Your browser doesn't support javascript.
loading
[Successful unrelated cord blood transplantation for extensive meningeal juvenile xanthogranuloma developing after treatment of Langerhans cell histiocytosis in a child].
Sako, Masahiro; Ishii, Takefumi; Okada, Keiko; Mochizuki, Takahiro; Hara, Junichi; Kudo, Ko; Imashuku, Shinsaku.
Afiliação
  • Sako M; The First Hospital of Welfare-Medical Association.
  • Ishii T; Department of Pediatric Hematology and Oncology, Osaka City General Hospital.
  • Okada K; Ishii Children's Clinic.
  • Mochizuki T; Department of Pediatric Hematology and Oncology, Osaka City General Hospital.
  • Hara J; Department of Pediatric Hematology and Oncology, Osaka City General Hospital.
  • Kudo K; Kibono Mori Developmental Growth Clinic.
  • Imashuku S; Department of Pediatric Hematology and Oncology, Osaka City General Hospital.
Rinsho Ketsueki ; 61(5): 468-473, 2020.
Article em Ja | MEDLINE | ID: mdl-32507810
ABSTRACT
A 2-year and 4-month-old boy developed Langerhans cell histiocytosis (LCH) at the left parietal region of the skull. After treatment with chemotherapy, the patient achieved remission but experienced three relapses. After 3 years, he complained of headache, blurred vision, and lethargy. Brain magnetic resonance imaging revealed multiple dura-based meningeal masses. Biopsy was performed, and the patient was then diagnosed with juvenile xanthogranuloma (JXG). The analysis of both LCH/JXG tissues revealed BRAF V600E mutation. The JXG masses were not responsive to prednisolone, which was injected locally, radiotherapy (24 Gy), and chemotherapy (2-chlorodeoxy-adenosine). In addition, since the patient developed macrophage activation syndrome associated with systemic JXG progression, he received unrelated cord blood transplantation (u-CBT) at the age of 10 years and 11 months. Engraftment was performed at day 42, and significant GVHD was not observed. Four months after CBT, the patient was treated with infliximab (Remicade®) and dexamethasone palmitate (Limethasone®). The size of the intracranial JXG masses gradually decreased after u-CBT and disappeared after 4 years. Currently, the patient is doing well at the age of 25 years and is receiving androgen replacement therapy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Histiocitose de Células de Langerhans / Xantogranuloma Juvenil / Transplante de Células-Tronco de Sangue do Cordão Umbilical Idioma: Ja Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Histiocitose de Células de Langerhans / Xantogranuloma Juvenil / Transplante de Células-Tronco de Sangue do Cordão Umbilical Idioma: Ja Ano de publicação: 2020 Tipo de documento: Article